Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2018; 07(03): 170-187
DOI: 10.4103/sajc.sajc_63_18
Letter to the Editor

Isolated central nervous system blast crisis in a case of chronic myeloid leukemia on dasatinib

P.K Kiran
Department of Medical Oncology, Healthcare Global Enterprises Hospital, Bengaluru, Karnataka
,
Girish V. Badarke
Department of Hematology, Healthcare Global Enterprises Hospital, Bengaluru, Karnataka
,
C.N Suresh
Department of Hematology, Healthcare Global Enterprises Hospital, Bengaluru, Karnataka
,
B.J Srinivas
Department of Medical Oncology, Healthcare Global Enterprises Hospital, Bengaluru, Karnataka
,
Radheshyam Naik
Department of Medical Oncology, Healthcare Global Enterprises Hospital, Bengaluru, Karnataka
› Author Affiliations Source of Support: Nill.
› Further Information
  PDF Download Permissions and Reprints


Publication History

Article published online:
22 December 2020

© 2018. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Greer JP, Arber DA, Glader B, List AF, Means RT Jr., Paraskevas F, et al. Wintrobe's Clinical Hematology. 13th ed. UK:LWW;2013.
  • 2 Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haemotopietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008.
  • 3 Rajappa S, Uppin SG, Raghunadharao D, Rao IS, Surath A. Isolated central nervous system blast crisis in chronic myeloid leukemia. Hematol Oncol 2004;22:179-81.
  • 4 Pfeifer H, Wassmann B, Hofmann WK, Komor M, Scheuring U, Brück P, et al. Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Clin Cancer Res 2003;9:4674-81.
  • 5 Altintas A, Cil T, Kilinc I, Kaplan MA, Ayyildiz O. Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: A case report. J Neurooncol 2007;84:103-5.
  • 6 Oshima K, Kanda Y, Yamashita T, Takahashi S, Mori T, Nakaseko C, et al. Central nervous system relapse of leukemia after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2008;14:1100-7.
  • 7 Papageorgiou SG, Pappa V, Economopoulou C, Tsirigotis P, Konsioti F, Ionnidou ED, et al. Dasatinib induces long-term remission in imatinib-resistant Philadelphia chromosome-positive acute megakaryoblastic leukemia but fails to prevent development of central nervous system progression. Leuk Res 2010;34:e254-6.
  • 8 Frigeri F, Arcamone M, Luciano L, Di Francia R, Pane F, Pinto A, et al. Systemic dasatinib fails to prevent development of central nervous system progression in a patient with BCR-ABL unmutated Philadelphia chromosome-positive leukemia. Blood 2009;113:5028-9.